The American Hospital Association (AHA), ASHP, and the Federation of American Hospitals (FAH) are fielding a survey to all community hospitals and health systems to collect quantitative, representative data on pharmaceutical drug spending and the impact of drug shortages. Read More »
The leading global biotechnology company focused on rare diseases announces today that it has entered into a definitive agreement with Servier S.A.S. (“Servier”) to sell its Oncology business for $2.4 billion. Read More »
Online Training Education Program Readies Pharmacists, Technicians to Prepare Sterile Products Read More »
Just announced that the company is beginning two Phase 3 studies of PCV-15 (V114), its investigational polyvalent conjugate vaccine for the prevention of pneumococcal disease. Read More »
Tagrisso delivered unprecedented median progression-free survival of 18.9 months versus 10.2 months compared with current standard of care Read More »
The global biotechnology leader in rare disease, just announced the U.S. Food and Drug Administration (FDA) has approved VONVENDI [von Willebrand factor (recombinant)], a recombinant von Willebrand factor (rVWF) treatment for perioperative management of bleeding in adults (age 18 and older) with von Willebrand disease (VWD).1 VONVENDI is also indicated for on-demand treatment and control of bleeding episodes, and it is the first and only recombinant treatment for adults living with VWD, the most common inherited bleeding disorder.1,3-4 Read More »
New Guidelines Call for Standardized Approach to Managing Investigational Drug Products Read More »
The man looked to be in his mid to late 30s and, at a glance, not someone who a stranger would suspect of having a substance use disorder, said Michelle Maguire, emergency medicine pharmacy resident at Massachusetts General Hospital in Boston. Read More »
The trial compared Lynparza with chemotherapy (physician’s choice of capecitabine, eribulin or vinorelbine) for patients with germline BRCA-mutated (gBRCAm) HER2-negative metastatic breast cancer and met its primary endpoint of progression-free survival (PFS). Read More »
The Centers for Disease Control and Prevention (CDC) has issued an outbreak alert informing clinicians about reports of potentially life-threatening hemorrhage associated with the use of synthetic cannabinoids. Read More »
The unprecedented progression-free survival benefit for 1st-line Tagrisso demonstrated in the FLAURA trial is preserved through subsequent lines of therapy Read More »
Hospitals that are visited by surveyors from the Joint Commission need to demonstrate the existence of and adherence to policies for reviewing overrides for medications kept in automated dispensing cabinets (ADCs). Read More »
Just announced that an agreement has been completed for the transfer of certain Agensys research facilities in Santa Monica, California, USA, to Kite. The asset transfer was completed on April 12, 2018. Additional financial information or further deal terms are not being disclosed. Read More »
In reviewing several legislative proposals to combat the nation’s opioid crisis, members of a House of Representatives subcommittee on February 28 opined on the need for healthcare providers to receive special training on prescribing and dispensing opioid-containing products. Read More »
An a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, is supporting the presentation of three accepted scientific presentations at the National Lipid Association (NLA) Scientific Sessions in Las Vegas, NV, April 26-29, 2018. Read More »
A hearing of the House Energy and Commerce Committee’s health subcommittee on the opioid epidemic, Rep. Cathy McMorris Rodgers (R-Wash.) discussed the pharmacist’s role in delivering patient care to Medicare beneficiaries and noted her support for legislation that allows pharmacists to care for patients in certain underserved areas. Specifically, she mentioned the benefits of H.R. 592, the Pharmacy and Medically Underserved Areas Enhancement Act, and submitted a letter of support from the Washington Pharmacy Association. Read More »
Just announced full results from the Phase 3b LIBERTY trial of Aimovig™ (erenumab) in episodic migraine patients who had previously failed two to four preventive treatments, due to lack of efficacy or to intolerable side effects. Read More »
ASHP’s 2018 Match concluded today, as 4,777 individuals matched with more than 2,300 pharmacy residency programs across the country. Read More »
AbbVie (NYSE: ABBV) announced global resolution of all intellectual property-related litigation with Samsung Bioepis over its proposed biosimilar adalimumab product. Read More »
These analyses highlight the need for further research in patients with reduced kidney function in conjunction with diabetes mellitus or ongoing inflammation, as denoted by elevated high sensitivity C-reactive protein (hsCRP) levels, and persistent high triglycerides (TG) despite statin therapy due to the association with increased cardiovascular disease (CVD) risk. Read More »
Alerts Sign-up
